Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SHC016

Sigma-Aldrich

MISSION® pLKO.1-puro Non-Target shRNA Control Plasmid DNA

Targets no known genes from any species

Synonyme(s) :

MISSION® Control Vectors, negative control, negative shRNA control, non-target control, non-target shRNA, non-target shRNA control, shRNA control

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
41106609
Nomenclature NACRES :
NA.51

Niveau de qualité

Gamme de produits

MISSION®

Concentration

500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)

Conditions d'expédition

dry ice

Température de stockage

−20°C

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

The MISSION pLKO.1-puro Non-Target shRNA Control Plasmid DNA is a lentivirus plasmid vector. The vector contains an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION shRNA library clones. This allows one to examine the effect of transfection of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Plasmid DNA is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.

Application

MISSION® pLKO.1-puro non-target shRNA control plasmid DNA has been used as a control during transduction:
  • in tumor cells for multicolour imaging
  • in human adult low calcium temperature keratinocytes
  • in mouse embryonic fibroblasts, to study the biological functions of IP6K1 (inositol hexakisphosphate kinase)
  • to study the function of Zac1 (zinc finger protein regulating apoptosis and cell cycle arrest) expression in astroglial differentiation
To see more application data, protocols, vector maps visit sigma.com/shrna.

Informations légales

Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human keratinocytes
Avitabile D, et al.
The International Journal of Biochemistry & Cell Biology, 53(7580), 24-34 (2014)
Deletion of inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration and invasion, conferring protection from aerodigestive tract carcinoma in mice
Jadav RS, et al.
Cellular Signalling, 28(8), 1124-1136 (2016)
Brain tumour cells interconnect to a functional and resistant network
Osswald M, et al.
Nature, 528(7580), 93-93 (2015)
Sophie Weil et al.
Neuro-oncology, 19(10), 1316-1326 (2017-04-19)
Primary and adaptive resistance against chemo- and radiotherapy and local recurrence after surgery limit the benefits from these standard treatments in glioma patients. Recently we found that glioma cells can extend ultra-long membrane protrusions, "tumor microtubes" (TMs), for brain invasion
Murali R Kuracha et al.
PloS one, 12(6), e0179510-e0179510 (2017-06-24)
Mucinous colorectal adenocarcinomas (MCAs) are clinically and morphologically distinct from nonmucinous colorectal cancers (CRCs), show a distinct spectrum of genetic alterations (higher KRAS mutations, lower p53, high MUC2), exhibit more aggressive behavior (more prone to peritoneal dissemination and lymph node

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique